THOUSAND OAKS, Calif. – Biotechnology company Amgen Inc., which has a manufacturing plant in West Greenwich, and France-based pharmaceuticals company Servier announced a collaboration agreement that allows the exchange of rights to various cardiovascular disease therapies between the two companies.
Through the collaboration Amgen has gained commercial rights in the U.S. to Servier’s oral drug treatment for chronic heart failure, ivabradine or Procoralan in the EU. The company has also gained rights to commercialize a Servier molecule that is currently in development for cardiovascular diseases.
“Amgen is pleased to enter into this collaboration with Servier to bring potential new cardiovascular treatment options to patients in both the U.S. and Europe,” Amgen’s Executive Vice President of Research and Development Dr. Sean E. Harper said in a statement. “Ivabradine, an ifinhibitor, offers a novel alternative approach for patients with elevated heart rates.”
Servier obtained rights to commercialize in Europe an activator that is being tested to treat heart failure in patients with systolic dysfunction
Amgen will make an upfront payment of $50 million to Servier. It will also make payments for future royalties for ivabradine.
“Servier is very pleased to establish a collaboration with Amgen,” said Dr. Jean-Philippe Seta, CEO of Servier, in a statement. “This is a clear recognition of the medical value of ivabradine, one of our major cardiovascular innovations, which could also benefit U.S. patients.”
Estate and Corporate Income Taxes are changing next year, and business owners and executives should know the details. The PBN Summit on November 6th will provide those details and more - including how much Obamacare's Employer Mandate could cost.
PBN's annual Book of Lists has been an essential resource for the local business community for almost 30 years. The Book of Lists features a wealth of company rankings from a variety of fields and industries, including banking, health care, real estate, law, hospitality, education, not-for-profits, technology and many more.